The first CRISPR Therapeutics and Vertex collaboration to treat sickle cell disease (SCD), as well as β-thalassemia, was placed on a clinical hold by the FDA earlier this year.
The stock for CRISPR Therapeutics and other gene editing companies have been on a roller coaster ride during this clinical hold as well as after some damaging reports about the efficacy of CRISPR-Cas9.
Both pharmaceutical companies remain on track to start their Phase 1/2 clinical trial for SCD and β-thalassemia.
TheFutureGist 